Loading stock data…
MNOV
$1.27-0.03 (-2.31%)
After Hours$1.27+0.00 (+0.00%)· Last close Jun 9
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MediciNova, Inc. in the Healthcare sector is trading at $1.27. Wall Street consensus targets $9.00 (3 analysts), implying a +608.7% move over the next 12 months. The stock is currently near its 52-week low of $1.17, remaining 9.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +608.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.27
Potential Downside
0%
Whystock Fair Value$1.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.74%
Volume
Today's trading volume
14,872
Recent News
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
MediciNova: Q4 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Friday reported a loss of $2.8 million in its fourth quarter.
ATA Creativity Global Among 3 Promising Penny Stocks
As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by...
MediciNova: Q3 Earnings Snapshot
LA JOLLA, Calif. AP) — MediciNova Inc. MNOV) on Wednesday reported a loss of $3.1 million in its third quarter.